ストックスクリーナーアプリを入手
11.71
1.39%
0.16
アフターアワーズ：
11.71
前日終値:
$11.55
開ける：
$11.65
24時間の取引高:
305.23K
Relative Volume:
0.75
時価総額：
$230.89M
収益：
$244.06M
当期純損益:
$87.01M
株価収益率:
6.4295
EPS:
1.8213
ネットキャッシュフロー:
$105.95M
1週間 パフォーマンス:
-6.69%
1か月 パフォーマンス:
+6.26%
6か月 パフォーマンス:
-19.19%
1年 パフォーマンス:
-10.54%
1日の値動き範囲:
$11.55
$11.84
1週間の範囲:
$10.78
$12.63
52週間の値動き範囲:
$10.41
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
名前
Keros Therapeutics Inc
セクター
電話
617-314-6297
住所
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.71 | 227.74M | 244.06M | 87.01M | 105.95M | 1.8213 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-01-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-12-16 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-16 | 繰り返されました | Oppenheimer | Outperform |
| 2024-12-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-12 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-12-12 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 開始されました | Jefferies | Buy |
| 2024-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-23 | 開始されました | Guggenheim | Buy |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-02-21 | 開始されました | William Blair | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-07-31 | 開始されました | Wedbush | Outperform |
| 2023-07-26 | 開始されました | BofA Securities | Buy |
| 2023-02-14 | 開始されました | Cowen | Outperform |
| 2022-10-18 | 開始されました | Truist | Buy |
| 2022-07-26 | 開始されました | BTIG Research | Buy |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | Jefferies | Buy |
| 2020-05-04 | 開始されました | Piper Sandler | Overweight |
| 2020-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Keros Therapeutics Inc (KROS) 最新ニュース
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 24.9% in March - MarketBeat
Understanding the Setup: (KROS) and Scalable Risk - Stock Traders Daily
Wall Street Recap: Can Keros Therapeutics Inc weather a recessionWeekly Gains Report & Risk Managed Investment Strategies - baoquankhu1.vn
Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN
Wedbush Maintains Keros Therapeutics (KROS) Neutral Recommendation - MSN
KROS SEC FilingsKeros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
BlackRock (KROS) reports 1.99M-share, 10.1% passive stake in Keros Therapeutics - Stock Titan
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Keros Therapeutics (KROS) CEO exercises options for 55,000 shares - Stock Titan
JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. $KROS Shares Acquired by SG Americas Securities LLC - MarketBeat
Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report? - Yahoo Finance
The Technical Signals Behind (KROS) That Institutions Follow - Stock Traders Daily
Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? - MSN
KROS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
[144] Keros Therapeutics, Inc. SEC Filing - Stock Titan
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock? - qz.com
Keros Therapeutics (KROS) awards 80,000 stock options to Chief Legal Officer - Stock Titan
Vanguard disaggregates holdings; reports 0 KROS shares (KROS) - Stock Titan
Fed Meeting: What are Keros Therapeutics Incs technical support levels2026 Dividend Review & Fast Gain Swing Alerts - baoquankhu1.vn
KROS stock: What to know about Rinvatercept in DMD - MSN
Chart Watch: What is Keros Therapeutics Incs P E ratio telling us2026 Year in Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Institution Moves: Can Keros Therapeutics Inc weather a recessionM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn
Published on: 2026-03-25 15:00:50 - baoquankhu1.vn
Pulmonary Arterial Hypertension Market: Expanding Revenue Landscape to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics - Barchart.com
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from S&P Biotechnology Select Industry Index - MarketScreener
Precision Trading with Keros Therapeutics Inc. (KROS) Risk Zones - Stock Traders Daily
Quarterly Trades: Is now the right time to enter Keros Therapeutics Inc2026 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn
Block Trades: Will RIVN benefit from current market trendsQuarterly Risk Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Can Keros Therapeutics Rinvatercept stand out in the DMD market? - MSN
Targets Report: Is Keros Therapeutics Inc likely to announce a buyback2026 EndofMonth & Expert Curated Trade Setup Alerts - baoquankhu1.vn
KROS: Does the Discounted Book Value Represent a Value Trap? - Bitget
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026 - sharewise.com
KROS Stock: Key Information on Rinvatercept for DMD - Bitget
KROS Pipeline Catalysts: DMD Phase II Progress and ALS Strategy for 2026 - Bitget
KROS Stock: What to Know About Rinvatercept in DMD - Yahoo Finance
KROS PE Ratio & Valuation, Is KROS Overvalued - Intellectia AI
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart
Myelofibrosis Market: Strong Pharma Growth Forecast Through - openPR.com
Keros Therapeutics (KROS) director submits initial Form 3 ownership - Stock Titan
Keros Therapeutics Inc (KROS) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):